Coloplast Valuation

Q: What is the Fair Price of COLO B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

COLO B (DKK890) is trading below our estimate of [[fair value]] (DKK1509.27)

Is COLO B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COLO B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COLO B (DKK890) is trading below our estimate of fair value (DKK1509.27)

Significantly Below Fair Value: COLO B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COLO B?

Key metric: As COLO B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COLO B. This is calculated by dividing COLO B's market cap by their current earnings.
What is COLO B's PE Ratio?
PE Ratio	39.7x
Earnings	DKK 5.05b
Market Cap	DKK 200.37b

COLO B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.2x
Enterprise Value/EBITDA	27.1x
PEG Ratio	3.1x

Price to Earnings Ratio vs Peers

How does COLO B's PE Ratio compare to its peers?

The above table shows the PE ratio for COLO B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	59.8x
DEMANT Demant	22.8x	12.4%	DKK 57.7b
AMBU B Ambu	129.8x	28.1%	DKK 30.5b
EMBLA Embla Medical hf	31.3x	16.9%	DKK 15.3b
COO Cooper Companies	55.1x	23.0%	US$19.8b
COLO B Coloplast	39.7x	12.9%	DKK 200.4b

Price-To-Earnings vs Peers: COLO B is good value based on its Price-To-Earnings Ratio (39.7x) compared to the peer average (59.8x).

Price to Earnings Ratio vs Industry

How does COLO B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 Companies	Price / Earnings	Estimated Growth	Market Cap

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: COLO B is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is COLO B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COLO B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	39.7x
Fair PE Ratio	36.8x

Price-To-Earnings vs Fair Ratio: COLO B is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the estimated Fair Price-To-Earnings Ratio (36.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COLO B forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	DKK 890.00	DKK 923.24 +3.7%	9.3%	DKK 1,030.00	DKK 700.00	n/a	21
Nov ’25	DKK 871.80	DKK 913.33 +4.8%	11.0%	DKK 1,050.00	DKK 700.00	n/a	21
Oct ’25	DKK 876.40	DKK 913.60 +4.2%	11.0%	DKK 1,060.00	DKK 700.00	n/a	20
Sep ’25	DKK 920.20	DKK 911.35 -1.0%	11.3%	DKK 1,060.00	DKK 700.00	n/a	20
Aug ’25	DKK 896.00	DKK 905.90 +1.1%	11.0%	DKK 1,060.00	DKK 710.00	n/a	20
Jul ’25	DKK 832.40	DKK 895.40 +7.6%	10.5%	DKK 1,060.00	DKK 710.00	n/a	20
Jun ’25	DKK 824.80	DKK 909.89 +10.3%	10.2%	DKK 1,060.00	DKK 710.00	n/a	19
May ’25	DKK 836.40	DKK 917.05 +9.6%	10.9%	DKK 1,060.00	DKK 700.00	n/a	19
Apr ’25	DKK 932.40	DKK 897.32 -3.8%	10.3%	DKK 1,060.00	DKK 700.00	n/a	19
Mar ’25	DKK 917.00	DKK 871.79 -4.9%	10.1%	DKK 1,000.00	DKK 700.00	n/a	19
Feb ’25	DKK 799.80	DKK 823.74 +3.0%	9.8%	DKK 962.00	DKK 631.00	n/a	19
Jan ’25	DKK 772.00	DKK 816.56 +5.8%	10.3%	DKK 962.00	DKK 631.00	n/a	18
Dec ’24	DKK 788.60	DKK 817.67 +3.7%	10.1%	DKK 962.00	DKK 631.00	n/a	18
Nov ’24	DKK 750.20	DKK 848.78 +13.1%	9.2%	DKK 980.00	DKK 686.00	DKK 871.80	18
Oct ’24	DKK 747.60	DKK 865.24 +15.7%	9.9%	DKK 1,000.00	DKK 686.00	DKK 876.40	17
Sep ’24	DKK 788.00	DKK 907.53 +15.2%	10.1%	DKK 1,070.00	DKK 720.00	DKK 920.20	15
Aug ’24	DKK 826.60	DKK 928.88 +12.4%	9.9%	DKK 1,070.00	DKK 720.00	DKK 896.00	16
Jul ’24	DKK 853.20	DKK 915.44 +7.3%	11.0%	DKK 1,070.00	DKK 690.00	DKK 832.40	16
Jun ’24	DKK 874.80	DKK 915.44 +4.6%	11.0%	DKK 1,070.00	DKK 690.00	DKK 824.80	16
May ’24	DKK 980.80	DKK 912.94 -6.9%	10.0%	DKK 1,045.00	DKK 690.00	DKK 836.40	16
Apr ’24	DKK 901.80	DKK 902.63 +0.09%	9.8%	DKK 1,045.00	DKK 690.00	DKK 932.40	16
Mar ’24	DKK 800.20	DKK 903.13 +12.9%	10.2%	DKK 1,045.00	DKK 690.00	DKK 917.00	15
Feb ’24	DKK 839.00	DKK 907.33 +8.1%	9.7%	DKK 1,045.00	DKK 690.00	DKK 799.80	15
Jan ’24	DKK 812.00	DKK 918.87 +13.2%	7.7%	DKK 1,045.00	DKK 798.00	DKK 772.00	15
Dec ’23	DKK 859.80	DKK 937.00 +9.0%	11.4%	DKK 1,224.00	DKK 798.00	DKK 788.60	14
Nov ’23	DKK 840.00	DKK 948.29 +12.9%	12.2%	DKK 1,224.00	DKK 790.00	DKK 750.20	14

Analyst Forecast: Target price is less than 20% higher than the current share price.